Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

OBJECTIVES: Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by increased pulmonary fibrosis, lung function decline, acute exacerbations, decreased quality of life and increased mortality. Nintedanib may slow down disease progression, but long-term outcomes are unknown. We a...

Descripción completa

Detalles Bibliográficos
Autores principales: Westerink, Lotte, Nicolai, Jelmer Lennart Jens, Postma, Maarten Jacobus, van Boven, Job Frank Martien, Boersma, Cornelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440187/
https://www.ncbi.nlm.nih.gov/pubmed/35927409
http://dx.doi.org/10.1007/s41669-022-00354-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440187/
https://www.ncbi.nlm.nih.gov/pubmed/35927409
http://dx.doi.org/10.1007/s41669-022-00354-2

Ejemplares similares